Alexion Pharmaceuticals, Inc. (ALXN) Share are down -17.89% over the last three months: What’s Next?

    Alexion Pharmaceuticals, Inc. (ALXN) is owned by a number of high-value investors. Its largest direct holder is Ludwig N. Hantson Director and Chief Executive Officer with 170,836 shares. The second-largest direct holder is Paul J. Clancy Executive Vice President and Chief Financial Officer, with 95,677 shares of the company’s stock. In third place with 66,153 shares of ALXN is Felix J. Baker Independent Director.

    This company’s stock price was $97.53 at the previous market close, with its latest volume reaching 3,706,946. Compare that to its average daily volume of 2.21M. Given the fact that this stock has 249.62M shares outstanding, its current market value is sitting at $24.35B. This publicly-traded stock’s 60-month Beta is 1.64. Its Price to Sales ratio is 5.41, its Price to Cash Flow ratio is 11.65, and its Price to Book ratio is 2.15.

    ALXN stock has achieved a 5-day range of $94.93 to $114.21, with a total performance of -12.35% during that period. Meanwhile, in the past month of trading, this stock has traded in the range of $94.93 to $125.52, generating a -13.18% change during the period. In the past three months, this stock’s price has changed by -17.02%, trading in the range of $94.93 to $134.84.

    In the past 5 days, shares of ALXN have made a new high 1 time. In the last month, it has made a new high 7 times, and in the past 3 months, it has made a new high 11 times.

    Alexion Pharmaceuticals, Inc. (ALXN) stock currently has a Financial Strength score of 6.8/10. This is due to a combination of factors, including a Cash to Debt ratio of 0.77, an Equity to Asset ratio of 0.70, a Debt to Equity ratio of 0.27 and a Debt to EBITDA of 1.49. The Interest Coverage of this stock is 21.59, its Piotroski F-Score is 8, its Altman Z-Score is 4.19 and its Beneish M-Score is -2.08.

    This publicly-traded company’s Profitability and Growth score is 8/10, thanks to a combination of things: an Operating Margin of 41.88, a Net Margin of 29.64, a ROE of 14.20, and a ROC of 58.96. Similarly, this company’s 3-Year Total Revenue Growth Rate is 16.60, its 3-Year Total EBITDA Growth Rate is 1.50, and its 3-Year EPS w/o NRI Growth Rate is -19.50.

    Shifting focus now to Valuation and Return for ALXN, this company’s Price to Tangible Book is 13.30, its Price to Projected FCF is 1.31, its Price to DCF (Earnings Based) is 1.34, and its Price to Median PS Value is 0.39. This organization’s Price to Graham Number is 3.12. Meanwhile, its Earnings Yield (Joel Greenblatt) is 6.39 and its Forward Rate of Return (Yactman) is 8.08.

    Certain ratios provide helpful insights into how a stock is performing. The Quick Ratio for ALXN is sitting at 3.56, while its Current Ratio is 4.04 and its PEG Ratio is 3.67. This stock’s PB Ratio is 2.14, its PS Ratio is 4.88, its PE Ratio (TTM) is 16.47, its Forward PE Ratio is 8.04, and its PE Ratio without NRI is 16.47. Similarly, its Shiller PE Ratio is 50.13, its Price to Owner Earnings is 22.99, its Price to Free Cash Flow is 17.38 and its Price to Operating Cash Flow is 15.27.